3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
32
Myelodysplastic Syndromes
30
Leukemia, Myeloid, Acute
30
Multiple Myeloma
24
Lymphoma, Non-Hodgkin
24
Hodgkin Disease
24
Lymphoma
21
Leukemia
21
Graft vs Host Disease
21
Leukemia, Lymphocytic, Chronic, B-Cell
20
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
16
Myeloproliferative Disorders
15
Lymphoma, Mantle-Cell
15
Neoplasms
14
Tuberous Sclerosis
13
Lymphoma, Large B-Cell, Diffuse
13
Hematologic Neoplasms
12
Burkitt Lymphoma
12
Primary Myelofibrosis
11
Lymphoma, Follicular
11
Breast Neoplasms
11
Waldenstrom Macroglobulinemia
10
Sarcoma
10
Recurrence
10
Neoplasms, Plasma Cell
10
Neoplasm Metastasis
10
Lymphoma, B-Cell, Marginal Zone
10
Leukemia, Myelomonocytic, Chronic
10
Prostatic Neoplasms
9
Lymphangioleiomyomatosis
9
Interventions
cemiplimab
1
Transdermal Patch
1
Sirolimus
1
Prednisone
1
Everolimus
1
Doxorubicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Cutaneous Squamous Cell Carcinoma
×
Sirolimus
×
Clear all
NCT04339062
2025-04-23
CONTRAC
Dana-Farber Cancer Institute
Phase 1/2
Completed
12 enrolled
13 charts